RX Biosyent Inc

TMS (CNSX:TMS) is pleased to announce that it has entered into an exclusive
license agreement (the "License Agreement") with RX 110 Inc. ("RX") to
manufacture, import, market and sell in Canada filler products for stopping
mould at source (the "RX Products"). "RX Products are the world's only known
products that not only eliminate mould at source - but assure effectiveness for
up to 99 years of service. And notably RX Products are still sold at the same
price as current fillers in the marketplace" said Donald Meade, CEO of RX110
Inc.


Pursuant to the terms of the License Agreement, and as compensation for RX
entering into the License Agreement, TMS has agreed to issue to RX 10,000,000
shares in the capital of TMS (the "Compensation Shares") and grant an ongoing
royalty equal to 3% of all TMS revenues generated by TMS from the sale of RX
Products. The term of the License Agreement shall continue until the expiration
of the last of the RX patents.


Reflecting the transaction, Donald Meade will be appointed as an officer of TMS
and elected to the board of directors of TMS at the next annual meeting of
shareholders. Completion of the transaction and the issuance of the Compensation
Shares is subject to the receipt of any and all necessary regulatory approvals.


There are 17,470,003 common shares issued and outstanding of TMS.

Biosyent (TSXV:RX)
Historical Stock Chart
From May 2024 to Jun 2024

Biosyent (TSXV:RX)
Historical Stock Chart
From Jun 2023 to Jun 2024